GILD · News · 20261107N
Acquisition-Related R&D Charges
GILEAD SCIENCES, INC. · 2026-11-07 · Importance 52 · Surprise 42 · In source text
Gilead recorded about $12 billion in acquired in-process R&D charges tied to deal accounting in a single quarter. The article identifies these charges as the primary reason for the company’s negative trailing-twelve-month EPS of -$3.13. The reported charge exceeds the stated materiality threshold of 249.
Key facts
- Gilead Sciences' negative earnings were primarily attributed to about $12 billion in acquired in-process R&D charges in a single quarter. source
- Gilead Sciences reported a trailing twelve-month EPS of -$3.13. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -144.6% | Gilead Sciences' negative earnings were primarily attributed to about $12 billion in acquired in-process R&D charges in a single quarter. |